Cannabis Legalization 2021: CBD Legality in the World
Legal status of cannabis in the European Union (as of 25 September 2026)
- The EU has no single cannabis law: it sets a common framework for hemp farming, trade and drug trafficking, while recreational use is regulated by each Member State.
- CBD lawfully produced in one Member State may in principle be sold in another; a national ban is allowed only if it is suitable to protect public health and does not go beyond what is necessary. The Court held that such CBD is not a narcotic drug under the 1961 Single Convention (Articles 34 and 36 TFEU, Case C-663/18 Kanavape, paras 76 and 96).
- Industrial hemp qualifies for CAP direct payments only if the THC content of the variety does not exceed 0.3 % (Art. 4(4) Regulation (EU) 2021/2115); THC control methods are set by the Commission (Art. 60(4)(a) Regulation (EU) 2021/2116).
- Member States may restrict how hemp is grown, for example ban indoor hydroponic cultivation, if the restriction is suitable and proportionate for protecting public health (Case C-793/22 Biohemp Concept, 4 October 2024).
- Member States must make intentional unlawful cultivation of cannabis plants and drug trafficking a criminal offence (Art. 2(1)(b) Framework Decision 2004/757/JHA, as quoted in Case C-271/23).
- Rules on recreational cannabis differ widely: Germany allows adults to possess up to 25 g in public, 50 g at home and three plants (§ 3 and § 9 KCanG), while in Czechia personal use becomes a criminal offence only above 5 plants, 200 g at home or 50 g elsewhere, and plants with up to 1 % THC are excluded (§ 285 Czech Criminal Code).
“Články 34 a 36 SFEU musí být vykládány v tom smyslu, že brání vnitrostátní právní úpravě, která zakazuje uvádět na trh CBD, který je legálně vyprodukován v jiném členském státě, v případě, že je extrahován z celé rostliny cannabis sativa, a nikoli pouze z jejích vláken a semen, ledaže je tato právní úprava s to zaručit naplnění cíle ochrany veřejného zdraví a nepřekračuje meze toho, co je k dosažení tohoto cíle nezbytné.”
[Translation: “Articles 34 and 36 TFEU must be interpreted as precluding national legislation which prohibits the marketing of CBD lawfully produced in another Member State when it is extracted from the Cannabis sativa plant in its entirety and not solely from its fibre and seeds, unless that legislation is appropriate for securing the attainment of the objective of protecting public health and does not go beyond what is necessary for that purpose.”]
This overview is based on legislation and case law in the legal database Europaius. It is not legal advice.
Cannabidiol (CBD) has radically transformed the European cannabis landscape. This non-psychoactive cannabinoid has opened new prospects for seed collectors and genetics enthusiasts, creating a complex but fascinating market for collectible genetic material.
The legal situation of CBD in Europe presents a mosaic of regulations that vary significantly from country to country. While some states have embraced liberal approaches, others maintain stricter restrictions. For cannabis seed collectors, understanding these differences is essential for navigating the collectible genetics market.
The CBD Regulatory Framework in Spain
Spain presents a particularly interesting scenario regarding CBD regulation. Before January 2019, the Spanish market offered a wide range of products containing cannabidiol. However, the implementation of the EU Novel Food Regulation drastically changed this situation.
The Novel Food Regulation classifies as a "novel food" any substance that was not consumed in significant quantities by European citizens before May 15, 1997. Spain has chosen to adhere strictly to this regulation, resulting in severe restrictions for products intended for human consumption.
The Spanish Agency for Food Safety and Nutrition (AECOSAN) has mandated the withdrawal from the market of all CBD products intended for ingestion, including oils, capsules, and food supplements. However, products for external use, such as cosmetics and topical preparations, remain legally marketable.
For genetics collectors, Spain maintains a permissive approach. Domestic cultivation of CBD-rich varieties remains legal for private use, and the country hosts numerous registered cannabis clubs in major cities. Commercial cultivation of industrial hemp continues to be permitted for EU-certified varieties with a THC content below 0.2%.
The French Situation: Regulatory Complexity and Recent Developments
France presents one of the most complex regulatory frameworks in Europe regarding CBD. French regulations originally required a THC content of 0% in finished products, creating a practically impossible situation to comply with, given that even industrial hemp varieties contain natural traces of THC.
The French Interministerial Mission for Combating Drugs and Addictive Behaviors (MILDECA) subsequently established a tolerance for products with a THC content of up to 0.2%. This regulatory discrepancy has generated numerous legal disputes and situations of uncertainty for industry operators.
A landmark case involved two entrepreneurs from Marseille, convicted for selling CBD e-cigarettes. Despite their products complying with the 0.2% THC limit, they were prosecuted because the CBD was extracted from flowers and leaves imported from the Czech Republic, while French law only permitted the use of seeds and fibers.
The European Court of Justice subsequently declared the French ban on CBD illegal, ruling that it violated EU rules on the free movement of goods. Currently, French citizens can purchase CBD products derived from hemp plants with a THC content not exceeding 0.2%.
In 2021, the French National Assembly published a report containing 20 proposals to modernize hemp regulation, including the possibility of using the entire plant for industrial and commercial purposes, and raising the permitted THC limit in crops.
The Netherlands: The Cannabis Tolerance Paradox
The Netherlands, despite its reputation as a cannabis-friendly destination, maintains a surprisingly restrictive approach toward CBD. While Amsterdam's famous coffeeshops can sell THC-containing cannabis, CBD is subject to specific regulations under the Opium Act.
Under Dutch legislation, CBD oil technically remains illegal because it meets the definition of "cannabis oil" and contains traces of THC. However, the Opium Act protects CBD from the EU Novel Food Regulation, allowing commercialization under specific conditions:
- THC content not exceeding 0.05%
- Derivation from EU-approved commercial hemp varieties
- Absence of medical claims in promotional materials
- Maximum recommended daily dose of 160mg of CBD
CBD products are available in headshops, coffeeshops, and natural product stores, creating a peculiar market where high-THC cannabis is tolerated but CBD is more strictly regulated.
Germany: Toward a More Liberal Approach
Germany has developed one of the clearest and most permissive frameworks for CBD in Europe. German citizens can purchase CBD products in specialized stores, pharmacies, and online retail outlets, provided they comply with the established THC content limits.
The German market has embraced the diversification of CBD products, offering not only oils and capsules but also cosmetics, pet products, and a wide range of topical preparations. This openness has made Germany one of the reference markets for the European CBD industry.
For collectors of CBD-rich seeds, Germany represents a mature market where genetic research and the development of innovative varieties are particularly advanced. The country hosts numerous companies specializing in the development of unique terpene profiles and the stabilization of genetic lines with high cannabidiol content.
Future Prospects for the European CBD Market
The European CBD regulatory landscape continues to evolve rapidly. Recent decisions by the European Court of Justice have established important principles regarding the free movement of CBD products legally produced in EU member states.
For collectors of genetic material, these regulatory developments open new possibilities for the acquisition and study of varieties from different European countries. The growing acceptance of CBD as a non-psychoactive substance is facilitating scientific research on the cannabinoid and terpene profiles of different genetics.
The collectible seed industry benefits from this greater regulatory clarity, allowing genetics enthusiasts to explore the aromatic properties and chemical characteristics of innovative varieties developed throughout Europe. The diversity of terpene profiles and genetic stability represent increasingly important criteria for specialized collectors.